Analysis of Care for Patients with Castration-Resistant Prostate Cancer (CRPC)
A retrospective secondary data analysis on clinical characteristics, treatment patterns and treatment costs, especially to identify Xofigo’s position in real life treatment pathway of CRPC patients.
: - All patients with a final diagnosis of mCRPC (=indication for the treatment with Xofigo) archived in ContraCare’s reimbursement database
No Exclusion Criteria Available
Analysis of Care for Patients with Castration-Resistant Prostate Cancer (CRPC) treated with Xofigo in Germany